Understanding rhabdomyolysis induced acute kidney injury in patients with COVID-19  

作　　者：Alexander Ikanović Karan Varshney 

机构地区：[1]School of Medicine,Deakin University,Waurn Ponds,VIC 3216,Australia [2]School of Public Health and Preventive Medicine,Monash University,Melbourne,VIC 3004,Australia

出　　处：《World Journal of Virology》2024年第4期139-142,共4页世界病毒学杂志（英文）

摘　　要：This work comments on an article published in the recent issue of the World Journal of Virology.Rhabdomyolysis is a complex condition with symptoms such as myalgia,changes to urination,and weakness.With the potential for substantial kidney impairment,it has also been shown to be a severe complication of coronavirus disease 2019(COVID-19).To date,various theoretical explanations exist for the development of rhabdomyolysis induced acute kidney injury(RIAKI)in COVID-19 infection,including the accumulation of released striated muscle myoglobin in the urine(myoglobinuria).In their article,they(2024)demonstrate in a retrospective study that RIAKI in COVID-19 patients tended to have elevated levels of C-reactive protein,ferritin,and procalcitonin.These patients also had poorer overall prognoses when compared to COVID-19 patients who have acute kidney injury(AKI)due to other causes.It is clear from these findings that clinicians must closely monitor and assess for the presence of rhabdomyolysis in COVID-19 patients who have developed AKIs.Moreover,additional research is required to further understand the mechanisms behind the development of RIAKI in COVID-19 patients in order to better inform treatment guidelines and protocols.

关 键 词：COVID-19 RHABDOMYOLYSIS Acute kidney injury MORTALITY COMPLICATION 

分 类 号：R563.1[医药卫生—呼吸系统]